ClinicalTrials.gg
CompletedNCT03931590Updated May 30, 2025

A Human AME Study for Omaveloxolone

A Phase 1 interventional study of [14C]-Omaveloxolone in Healthy Male Subjects, sponsored by Biogen. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-30.

Sponsored by Biogen · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2019, 7 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This study will assess the pharmacokinetics (PK), mass balance, metabolite profiles, and rates and routes of elimination of [14C] omaveloxolone and derived metabolites following administration as a single 150 mg (containing approximately 90 µCi) dose to healthy male subjects.

02

Conditions studied

  • Healthy Male Subjects

Keywords

  • RTA 408
  • RTA 408 capsules
  • omaveloxolone
  • omaveloxolone capsules
  • AME
  • mass balance
  • metabolite identification
03

In context

Lead sponsor

Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.

Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must satisfy all of the following criteria at the Screening Visit unless otherwise stated:
  • Males, of any race, between 18 and 55 years of age, inclusive.
  • (BMI) between 18.0 and 32.0 kg/m2, inclusive, and a total body weight > 50 kg.
  • Be surgically sterile or willing to agree to use
  • In good health, as assessed by the investigator (or designee).
  • Able to comprehend and willing to sign an ICF and to abide by the study restrictions.

Exclusion criteria

Exclusion Criteria:

  • Significant history or clinical manifestation of any major system disorder, as determined by the investigator (or designee).
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator (or designee).
  • History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs.
  • Presence of any other condition, including surgery, known to interfere with the absorption, distribution, metabolism, or excretion of medicines.
  • Abnormal laboratory values considered by the investigator.
  • Clinically significant abnormal 12-lead ECGs.
  • History of alcoholism or drug/chemical abuse within 2 years prior to Check-in (Day-1).
  • Alcohol consumption of > 21 units per week.
  • Positive urine drug screen at Screening, or positive alcohol breath test result or positive urine drug screen at Check-in (Day -1).
  • Positive hepatitis panel and/or positive test.
  • Participation in a clinical study involving administration of an drug (new chemical entity) in the past 30 days or 5 half-lives (if known) prior to dosing.
  • Current enrollment in another clinical study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Healthy Male Subjects

    Single oral dose of 150 mg of \[14C\] omaveloxolone containing approximately 90 μCi as a capsule after an overnight fast of at least 10 hours.

    Drug: [14C]-Omaveloxolone

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum concentration (Cmax) of omaveloxolone

    Pharmacokinetics will be assessed by blood sampling for omaveloxolone to determine maximum observed concentration (Cmax).

    Time frame: 22 days

  2. Area under the omaveloxolone concentration-time curve (AUC)

    Pharmacokinetics will be assessed by blood sampling for omaveloxolone to determine area under the curve (AUC).

    Time frame: 22 days

  3. Maximum concentration of total radioactivity in blood and plasma

    Mass balance and metabolite profiles will be assessed by blood sampling for omaveloxolone to determine maximum concentration of total radioactivity

    Time frame: 22 days

  4. Area under the concentration-time curve total radioactivity in blood and plasma

    Mass balance and metabolite profiles will be assessed by blood sampling for total radioactivity to determine area under the concentration-time curve.

    Time frame: 22 days

  5. Amount of radioactivity excreted in urine (Aeu)

    Rates and routes of elimination will be assessed by urine sampling for radioactivity.

    Time frame: 22 days

  6. Amount of radioactivity excreted in feces (Aef)

    Rates and routes of elimination will be assessed by sampling of feces for radioactivity.

    Time frame: 22 days

07

Study locations

1 site
  • Covance Clinical Research Unit (CRU) Inc.
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in May 2019, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2019
First posted
Apr 30, 2019
StartActual
Apr 11, 2019
Primary completionActual
May 31, 2019
CompletionActual
May 31, 2019
Last update
May 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03931590
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Apr 30, 2019
Start date
Apr 11, 2019
Primary completion
May 31, 2019
Completion
May 31, 2019
Last update
May 30, 2025

Study contacts

Nicholas Siebers, MD
principal investigator · Covance CRU Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omaveloxolone

Start the discussion